title: The use of connexin-based therapeutic approaches to target inflammatory diseases.
abstract: Alterations in Connexin43 (Cx43) expression levels have been shown to play a role in inflammatory processes including skin wounding and neuroinflammation. Cx43 protein levels increase following a skin wound and can inhibit wound healing. Increased Cx43 has been observed following stroke, epilepsy, ischemia, optic nerve damage, and spinal cord injury with gap junctional communication and hemichannel opening leading to increased secondary damage via the inflammatory response. Connexin43 modulation has been identified as a potential target for protection and repair in neuroinflammation and skin wound repair. This review describes the use of a Cx43 specific antisense oligonucleotide (Cx43 AsODN) and peptide mimetics of the connexin extracellular loop domain to modulate Cx43 expression and/or function in inflammatory disorders of the skin and central nervous system. An overview of the role of connexin43 in inflammatory conditions, how antisense and peptide have allowed us to elucidate the role of Cx43 in these diseases, create models of diseases to test interventions and their potential for use clinically or in current clinical trials is presented. Antisense oligonucleotides are applied topically and have been used to improve wound healing following skin injury. They have also been used to develop ex vivo models of neuroinflammatory diseases that will allow testing of intervention strategies. The connexin mimetic peptides have shown potential in a number of neuroinflammatory disorders in ex vivo models as well as in vivo when delivered directly to the injury site or when delivered systemically.
authors.affiliation: Department of Anatomy with Radiology, Faculty of Medical and Health Sciences, University of Auckland, Auckland, New Zealand.
authors.forename: Simon J
authors.initials: SJ
authors.lastname: O'Carroll
authors.forename: David L
authors.initials: DL
authors.lastname: Becker
authors.forename: Joanne O
authors.initials: JO
authors.lastname: Davidson
authors.forename: Alistair J
authors.initials: AJ
authors.lastname: Gunn
authors.forename: Louise F B
authors.initials: LF
authors.lastname: Nicholson
authors.forename: Colin R
authors.initials: CR
authors.lastname: Green
mesh_terms: D000818:Animals; D032701:Biomimetics; D018031:Connexin 43 / Q000378:metabolism; D017630:Connexins / Q000235:genetics / Q000378:metabolism*; D004195:Disease Models, Animal; D017629:Gap Junctions / Q000378:metabolism; D006624:Hippocampus / Q000378:metabolism / Q000473:pathology; D006801:Humans; D007249:Inflammation / Q000235:genetics / Q000378:metabolism* / Q000628:therapy; D016376:Oligonucleotides, Antisense / Q000235:genetics / Q000378:metabolism; D010446:Peptide Fragments / Q000494:pharmacology; D051381:Rats; D013116:Spinal Cord / Q000378:metabolism / Q000473:pathology; D014945:Wound Healing / Q000502:physiology
chemical_list: D018031:Connexin 43; D017630:Connexins; D016376:Oligonucleotides, Antisense; D010446:Peptide Fragments